heterozygous
To sponsor this category, click here | subscribe to this category

Mipomersen – It Still Works

Isis Pharmaceuticals has had a long, tough history developing antisense-based therapeutics. I’ve lost count of the number of promising candidates they’ve had (and promising deals they’ve signed). But the latest one seems to be progressing: mipomersen , designed to block production of the ApoB lipoprotein